RxDoctor Payments Data

Jarad Levin, MD

Dermatology · Oklahoma City, OKNPI 1407177538

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,824 of the $6,146 with a category attached, or 78.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,193, 3.8 times the $574 reported in 2019.

$6,146in general payments, 2019–2025

Across 74 payments — averaging $83.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Kyowa Kirin, Inc.$985
  • Arcutis Biotherapeutics, Inc.$596
  • AbbVie$564
  • UCB, Inc.$329
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$301
  • plus $2K from 17 others
$1,241,665in research payments, 2019–2025

Across 156 payments — averaging $7959.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$409K
  • Boehringer Ingelheim$311K
  • Novartis$148K
  • Pfizer$143K
  • Amgen$60K
  • Incyte Corporation$42K
  • plus $128K from 9 others

What the payments were for

  • Travel & lodging$96116%
  • Food & beverage$4,82478%
  • Education$3606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,146 in reported general payments places this provider in the 60th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$94,211
Medicare patients
485
Services billed
2,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$84,090
XolairOmalizumab12$44,095
Tacrolimus14$1,821
Ketoconazole55$1,181
Clobetasol Propionate21$877
Fluocinonide13$560
Dapsone15$408
Triamcinolone Acetonide21$406
Hydroxyzine Hcl11$125
Hydrocortisone11$100
Prednisone11$5

Paid to pharmacies, not to this prescriber.

Other dermatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →